Wells Fargo
SMMT icon

Wells Fargo’s Summit Therapeutics SMMT Stock Holding History

Wells Fargo’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$4.38K – 7184
2024
Q3 		$4.38K Buy
+200
New +$2.8K ﹤0.01% 5942

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wells Fargo's SMMT Position: Q1 2026 in Review

Wells Fargo reduced its Summit Therapeutics (SMMT) stake by 8.1% in Q1 2026, selling an estimated $171K and leaving 120,301 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3178.

Wells Fargo first reported a position in SMMT in Q3 2015 and has held it in 33 quarters since. The position peaked at $4.99M in Q2 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Wells Fargo held 120,301 shares of Summit Therapeutics worth $2.28M as of Q1 2026.
  • Wells Fargo sold 10,585 Summit Therapeutics shares in Q1 2026, an estimated $171K.
  • Summit Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3178 holding.
  • Wells Fargo first reported a position in Summit Therapeutics in Q3 2015 and has held it in 33 quarters since.
  • Wells Fargo's Summit Therapeutics position peaked at $4.99M in Q2 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.